Αρχική World News Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients... World News Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Από Ogkologos - 8 Ιουλίου, 2025 811 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Neoadjuvant Pembrolizumab Combined with Chemotherapy Followed by Adjuvant Pembrolizumab Significantly Improves... 15 Φεβρουαρίου, 2022 A Combination of Tucatinib and Trastuzumab Demonstrates Activity and Favourable Tolerability... 9 Οκτωβρίου, 2023 Stopping Treatment Is a Reasonable Strategy for Patients with Advanced NSCLC... 30 Ιουνίου, 2023 Implementation of Molecular Tumour Board Portal Developed Under the Umbrella of... 25 Μαΐου, 2022 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Extension of Indications for Venetoclax Study Adds to Debate about Screening for Melanoma Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with... Reducing Cancer’s Global Burden: A Conversation with NCI’s Dr. Satish Gopal